agents were categorized into two groups. Group A underwent testing without the administration of prophylactic Zofran; Group B received Zofran IV (0.1mg/kg) prophylactically prior to Glucagon administration. Results: Data was obtained from 14 consecutive patients prior to implementation of protocol (no Zofran), and 30 consecutive patients after. Without Zofran, 50% of patients experienced nausea/vomiting (7 of 14), whereas with Zofran, only 10% did (3 of 30). Zofran did not increase test failure rates; 71% (10 of 14) patients failed in the non-Zofran group, 56% (17 of the 30) failed in the Zofran group. Conclusion: Adding Zofran decreased nausea and vomiting without evidence of an increase in GHST failure rates. We evaluated failure rates because some of our physicians expressed concern that by reducing discomfort/stress during the test, GH levels might be lower; this does not appear to be the case. A limitation of this pilot study was that patients, pre and post Zofran protocol, were not matched for sociodemographic characteristics. Clinical Implications: Zofran administration prior to Glucagon reduces nausea and vomiting during GHST. The GHST failure rate was not higher in this small sample. Future studies with larger samples and matched control groups are needed to further study the outcomes of Zofran use in GHST.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.